

## AMENDMENTS TO THE CLAIMS

### IN THE CLAIMS

The following Listing of Claims, in which deleted text appears ~~struck through~~ and inserted text appears underlined, will replace all prior versions, and listings, of claims in the application.

### Listing of Claims

1-205. (Canceled)

206. (Currently amended) ~~The~~ An oligonucleotide compound of ~~claim 170, wherein said region consisting of 16 monomers, wherein adjacent monomers are covalently linked by a phosphodiester or a phosphorothioate linkage, and wherein the sequence of the oligonucleotide compound is~~ CTCAatccatggCAGC (SEQ ID NO: 130) or CTCAatccatggCAGc (SEQ ID NO: 130), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers.

207. (Canceled)

208. (Previously presented) The oligonucleotide compound of claim 206, wherein said compound is  $C_sT_sC_sA_s a_s t_s c_s c_s a_s t_s g_s g_s C_s A_s G_s C$  (SEQ ID NO: 664), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, and wherein the subscript "s" denotes a phosphorothioate linkage.

209. (Canceled)

210. (Currently amended) The oligonucleotide compound of claim ~~209~~ 206, wherein said compound is  $C_oT_oC_oA_o a_s t_s c_s c_s a_s t_s t_s g_s g_s C_oA_oG_oC$  (SEQ ID NO: 662), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, and wherein the subscript "s" denotes a phosphorothioate linkage and the subscript "o" denotes a phosphodiester linkage.

211. (Canceled)

212. (Currently amended) The oligonucleotide compound of claim ~~211~~ 206, wherein said compound is  $C_5T_5C_5A_5a_5t_5c_5c_5a_5t_5g_5g_5C_5A_5G_5c$  (SEQ ID NO: 661), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, and wherein the subscript "s" denotes a phosphorothioate linkage.

213. (Currently amended) The oligonucleotide compound of claim ~~170~~ 206, wherein said ~~region~~ compound is CTCAatccatggCAGC (SEQ ID NO: 130) or CTCAatccatggCAGc (SEQ ID NO: 130), wherein uppercase letters denote beta-D-oxy-LNA monomers, lowercase letters denote DNA monomers, and wherein the cytosine in each cytosine-containing beta-D-oxy-LNA monomer is 5-methyl cytosine.

214. (Canceled)

215. (Currently amended) The oligonucleotide compound of claim ~~214~~ 213, wherein said compound is  $C_5T_5C_5A_5a_5t_5c_5c_5a_5t_5g_5g_5C_5A_5G_5c$  (SEQ ID NO: 664), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript "s" denotes a phosphorothioate linkage, and wherein the cytosine in each cytosine-containing beta-D-oxy-LNA monomer is 5-methyl cytosine.

216. (Canceled)

217. (Currently amended) The oligonucleotide compound of claim ~~216~~ 213, wherein said compound is  $C_0T_0C_0A_0a_0t_0c_0c_0a_0t_0g_0g_0C_0A_0G_0c$  (SEQ ID NO: 662), wherein uppercase letters denote beta-D-oxy-LNA monomers, lowercase letters denote DNA monomers, the subscript "s" denotes a phosphorothioate linkage, the subscript "o" denotes a phosphodiester linkage, and wherein any cytosine in each cytosine-containing beta-D-oxy-LNA monomer is 5-methyl cytosine.

218. (Canceled)

219. (Currently amended) The oligonucleotide compound of claim ~~218~~ 213, wherein said compound is  $C_5T_5C_5A_5a_5t_5c_5c_5a_5t_5g_5g_5C_5A_5G_5c$  (SEQ ID NO: 661), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript "s" denotes a

phosphorothioate linkage, and wherein the cytosine in each cytosine-containing beta-D-oxy-LNA monomer is 5-methyl cytosine.

220. (Currently amended) The oligonucleotide compound of claim 219, wherein said compound is  $^{Me}C_sT_s^{Me}C_sA_sa_{ts}c_sC_sa_{ts}g_sg_s^{Me}C_sA_sG_sc$  (SEQ ID NO: 661), wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript "s" denotes a phosphorothioate linkage, and  $MeC \underline{C}^{Me}$  denotes a beta-D-oxy-LNA monomer containing 5-methyl cytosine.

221-224. (Canceled)